Table 4.
The effect of NAM treatment (NAM/vehicle) and TBI (vehicle/sham) on differentially expressed genes associated with significant functional categories and canonical pathways identified by IPA at 24 h post-TBI.
| Affymetrix ID | Gene symbol | Genes | 24 h post-TBI |
72 h post-TBI |
||
|---|---|---|---|---|---|---|
| NAM/vehicle | Vehicle/sham | NAM/vehicle | Vehicle/sham | |||
| 10726550 | Adam8 | ADAM metallopeptidase domain 8 | 0.59 | 2.11 | n.s. | 2.76 |
| 10759999 | Alox5ap | Arachidonate 5-lipoxygenase activating protein | 0.64 | 3.28 | n.s. | 3.85 |
| 10722992 | Anpep | Alanyl (membrane) aminopeptidase | 0.43 | 6.51 | n.s. | 10.18 |
| 10702214 | Arg1 | Arginase | 0.66 | 1.78 | n.s. | n.s. |
| 10780919 | Arl11 | ADP-ribosylation factor-like 11 | 0.58 | 3.74 | n.s. | 6.69 |
| 10797660 | Aspn | Asporin | 1.52 | n.s. | n.s. | n.s. |
| 10912112 | Bcl2a1 | BCL2-related protein A1 | 0.63 | 2.65 | n.s. | 5.48 |
| 10759834 | Brca2 | Breast cancer 2 | 0.61 | 1.66 | n.s. | n.s. |
| 10745677 | Ccl13l/Ccl3l3 | Chemokine (C–C motif) ligand 3-like 1 | 0.49 | 6.41 | n.s. | 3.39 |
| 10745670 | Ccl6 | Chemokine (C–C motif) ligand 6 | 0.42 | 6.19 | n.s. | 3.73 |
| 10736702 | Ccl7 | Chemokine (C–C motif) ligand 7 | 0.67 | 4.39 | n.s. | 3.35 |
| 10921163 | Ccr1 | Chemokine (C–C motif) receptor 1 | 0.53 | 4.11 | n.s. | 2.42 |
| 10853240 | Cd36 | CD36 molecule (thrombospondin receptor) | 0.57 | 5.26 | n.s. | 7.57 |
| 10825809 | Cd53 | Cd53 molecule | 0.61 | 3.99 | n.s. | 8.89 |
| 10865381 | Clec4e | C-type lectin domain family 4, member e | 0.39 | 10.51 | n.s. | 2.66 |
| 10862131 | Clec5a | C-type lectin domain family 5, member A | 0.66 | 4.11 | n.s. | 3.15 |
| 10871957 | Csf3r | Colony stimulating factor 3 receptor | 0.55 | 4.17 | n.s. | 3.72 |
| 10775896 | Cxcl3 | Chemokine (C-X-C motif) ligand 3 | 0.41 | 5.11 | n.s. | n.s. |
| 10924245 | Cxcr2 | Chemokine (C-X-C motif) receptor 2 | 0.51 | 5.77 | n.s. | 1.65 |
| 10787197 | Cyp4f18 | Cytochrome P450, family 4, subfamily 5, polypeptide 18 | 1.54 | 0.54 | n.s. | n.s. |
| 10827231 | Cyr61 | Cysteine-rich, angiogenic inducer, 61 | 0.66 | 3.95 | n.s. | 1.50 |
| 10794734 | F13a1 | Coagulation factor XIII, A1 polypepetide | 0.54 | 2.81 | n.s. | 3.41 |
| 10718934 | Fcar | IgA Fc receptor | 0.49 | 3.51 | n.s. | n.s. |
| 10769825 | Fcer1g | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | 0.62 | 3.39 | n.s. | 6.00 |
| 10825153 | Fcgr1a | Fc fragment of IgG, high affinity Ia, receptor | 0.59 | 3.78 | n.s. | 4.23 |
| 10769788 | Fcgr2a | Fc fragment of IgG, low affinity IIa, receptor | 0.53 | 3.44 | n.s. | 4.44 |
| 10727321 | Gal | Galaninprepropeptide | 0.63 | 4.25 | n.s. | 2.59 |
| 10902313 | Glipr1 | GLI pathogenesis-related 1 | 0.65 | 4.33 | n.s. | 5.43 |
| 10926967 | Gsta2 | Glutathione S-transferase alpha 2 | 1.63 | 0.42 | n.s. | n.s. |
| 10724311 | Hbb | Hemoglobin, beta | 0.62 | 2.91 | n.s. | 1.71 |
| 10758351 | Hcar2 | Hydroxycarboxylic acid receptor 2 | 0.56 | 2.39 | n.s. | n.s. |
| 10806946 | Hhip | Hedgehog-interaction protein | 1.56 | 0.46 | n.s. | n.s. |
| 10806122 | Hmox1* | Heme oxygenase (decycling) 1 | 0.56 | 8.47 | n.s. | 11.60 |
| 10761128 | Hspb1* | Heat shock protein | 0.54 | 3.19 | n.s. | 1.51 |
| 10725397 | Igsf6 | Immunoglobulin superfamily, member 6 | 0.60 | 4.52 | n.s. | 3.87 |
| 10849841 | Il1b* | Interleukin 1 beta | 0.62 | 3.10 | n.s. | n.s. |
| 10922816 | Il1r2 | Interleukin 1 receptor, type II | 0.49 | 3.81 | n.s. | n.s. |
| 10834109 | Il1rn* | Interleukin 1 receptor antagonist | 0.58 | 5.58 | n.s. | 4.88 |
| 10711299 | ltgax | Integrin, alpha X | 0.64 | 2.46 | n.s. | 2.19 |
| 10832306 | Itgb2 | Integrin, beta 2 | 0.63 | 3.27 | n.s. | 5.99 |
| 10890024 | Nfkbia | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 0.63 | 2.08 | n.s. | 1.68 |
| 10736312 | Niacr1 | Niacin receptor 1 | 0.56 | 2.39 | n.s. | n.s. |
| 10736312 | Nos2 | Nitric oxide synthase 2, inducible | 0.56 | 2.91 | n.s. | n.s. |
| 10761025 | Pilra | Paired immunoglobulin-like type 2 receptor alpha | 0.64 | 3.07 | n.s. | 2.90 |
| 10877907 | Plin2 | Perilipin 2 | 0.50 | 6.08 | n.s. | 6.17 |
| 10768138 | Ptprc | Protein tyrosine phosphatase, receptor type, C | 0.66 | 4.62 | n.s. | 9.39 |
| 10824695 | S100a9* | S100 calcium binding protein A9 | 0.52 | 3.73 | n.s. | 1.55 |
| 10883530 | Sdc1 | Syndecan 1 | 0.66 | 2.94 | n.s. | 2.25 |
| 10765186 | Sell | Selectin L | 0.51 | 4.70 | n.s. | 2.11 |
| 10826846 | Sgms2 | Sphingomyelin synthase 2 | 0.61 | 2.27 | n.s. | 2.46 |
| 10921120 | Slc6a20 | Solute carrier family 6 (proline IMINO transporter), member 20 | 1.70 | 1.99 | n.s | 2.72 |
| 10924286 | Slc11a1 | Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 | 0.60 | 3.76 | n.s. | 6.02 |
| 10851581 | Slpi | Secretory leukocyte peptidase inhibitor | 0.42 | 4.29 | n.s. | 3.41 |
| 10771919 | Sult1d1 | Sulfotransferase family 1D, member 1 | 1.53 | 0.48 | n.s. | 0.65 |
| 10719187 | Sult2a1 | Sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 | 0.66 | n.s. | n.s. | n.s. |
| 10934608 | Tlr13 | Toll-like receptor 13 | 0.61 | 3.02 | n.s. | 5.84 |
| 10881424 | Tnfrsf1b* | Tumor necrosis factor receptor superfamily, member 1b | 0.64 | 2.22 | n.s. | 2.84 |
| 10926277 | Trem1 | Triggering receptor expressed on myeloid cells 1 | 0.58 | 3.35 | n.s. | 5.43 |
Results are given as fold change with significance defined as 1.5-fold change, p < 0.05. The degree of differential expression of these genes is also shown for the NAM/Vehicle and Vehicle/Sham contrasts for the 72-h post-TBI time point.
*RT-PCR validated (see Figure 6).
n.s., not significant.